| abstract |
The peptide provided by the present invention is composed of the amino acid sequence represented by the general formula (I), and can accumulate in cancer-related fibroblasts. (Formula 1) X 11 -(Y 11 -X 12 ) n11 (I) (In the general formula (I), X 11 is a peptide residue consisting of the amino acid sequence of the following (a) or (b): (a) The amino acid sequence shown in any one of SEQ ID NOs: 1 to 4, (b) the amino acid sequence shown in any one of SEQ ID NO: 1 to 4 is obtained by deletion, substitution or addition of 1 or 2 amino acids Amino acid sequence; Y 11 is a peptide linker composed of amino acid residues with an amino acid number of 1 or more and 10 or less, and the amino acid residues are independently glycine residues, proline residues, serine residues, cysteine residues residue or lysine residue; X 12 is a peptide residue consisting of the amino acid sequence of (a) or (b), or their retro-inverted peptide residue; n11 is 0 or more than 9 the following integers). |